 <h1>Dolutegravir Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dolutegravir: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, dolutegravir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking dolutegravir:</p><p>
<i>Less common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blistering or peeling skin</li>
<li>bloody urine</li>
<li>burning, dry, or itching eyes</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>dark urine</li>
<li>decreased frequency or amount of urine</li>
<li>discharge or excessive tearing</li>
<li>fever</li>
<li>general feeling of discomfort or illness</li>
<li>general feeling of tiredness and weakness</li>
<li>increased thirst</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>muscle or joint aches</li>
<li>nausea</li>
<li>painful or difficult urination</li>
<li>rash with fever</li>
<li>redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>severe rash</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>swollen glands</li>
<li>troubled breathing</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>upper right abdominal or stomach pain</li>
<li>vomiting</li>
<li>weight gain</li>
<li>yellow eyes and skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Clay-colored stools</li>
<li>decreased appetite</li>
<li>headache</li>
<li>stomach pain or tenderness</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of dolutegravir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Itching skin</li>
<li>stomach discomfort</li>
<li>trouble sleeping</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Abnormal dreams</li>
<li>diarrhea</li>
<li>dizziness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Anxiety</li>
<li>difficulty in moving</li>
<li>joint pain or swelling</li>
<li>muscle cramp or stiffness</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dolutegravir: oral tablet, oral tablet dispersible</i></p><h3>General</h3><p>The most common side effects were diarrhea, nausea, and headache.  The most common side effects of moderate to severe intensity were insomnia, fatigue, and headache.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 18%), nausea (up to 13%), elevated lipase</p>
<p><b>Common</b> (1% to 10%): Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting<sup>[Ref]</sup></p><p>Grade 2 and grade 3 to 4 elevations in lipase were reported in up to 11% and up to 5% of therapy-naive patients, respectively.  Elevated lipase was reported in 10% of therapy-experienced integrase strand transfer inhibitor (INSTI)-experienced patients.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Dizziness<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Grade 2 and grade 3 to 4 elevations in AST were reported in up to 5% and up to 3% of therapy-naive patients, respectively.  Grade 2 and grade 3 to 4 elevations in ALT were reported in 4% and up to 2% of therapy-naive patients, respectively.  Grade 2 and grade 3 to 4 elevations in total bilirubin were reported in up to 3% and less than 1% of therapy-naive patients, respectively.  Elevated ALT and AST were reported in 9% and 8% of therapy-experienced INSTI-experienced patients, respectively.</p>
<p></p>
<p>The rates of AST and ALT abnormalities were higher patients coinfected with hepatitis B and/or C virus.  ALT abnormalities (grade 2 to 4) in hepatitis B and/or C coinfected patients compared with HIV monoinfected patients were reported in 18% versus 3% with 50 mg once a day and 13% versus 8% with 50 mg twice a day.</p>
<p></p>
<p>Liver chemistry elevations consistent with immune reconstitution syndrome were reported in some patients with hepatitis B and/or C at the start of therapy, especially when antihepatitis therapy was stopped.</p>
<p></p>
<p>Acute liver failure has been reported in a regimen containing this drug; contribution of this drug was unclear.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated AST, elevated ALT, elevated total bilirubin, hepatitis</p>
<p><b>Frequency not reported</b>: Liver chemistry elevations consistent with immune reconstitution syndrome</p>
<p><b>Postmarketing reports</b>: Acute liver failure, hepatotoxicity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperglycemia</p>
<p><b>Frequency not reported</b>: Fasted lipid values increased (including cholesterol, HDL cholesterol, LDL cholesterol, triglycerides)</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased glucose levels<sup>[Ref]</sup></p><p>Grade 2 and grade 3 hyperglycemia were reported in up to 9% and up to 2% of therapy-naive patients, respectively.  Hyperglycemia and elevated cholesterol were reported in 14% and 10% of therapy-experienced INSTI-experienced patients, respectively.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Suicidal ideation, attempt, behavior, or completion were observed primarily in patients with history of depression or other psychiatric illness.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Insomnia, abnormal dreams, depression</p>
<p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation, suicide attempt</p>
<p><b>Frequency not reported</b>: Suicidal behavior, suicide completion</p>
<p><b>Postmarketing reports</b>: Anxiety<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Grade 2 and grade 3 to 4 elevations in creatine kinase were reported in up to 5% and up to 7% of therapy-naive patients, respectively.  Elevated creatine kinase was reported in 6% of therapy-experienced INSTI-experienced patients.</p>
<p></p>
<p>Arthralgia and myalgia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated creatine kinase, myositis</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthralgia, myalgia<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Grade 2 and grade 3 to 4 reductions in total neutrophils were reported in up to 4% and up to 3% of therapy-naive patients, respectively.  Hematology laboratory abnormality (grade 3 to 4) was reported in 2% of therapy-experienced INSTI-experienced patients, with neutropenia (2%) reported most often.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased total neutrophils, hematology laboratory abnormality</p>
<p><b>Frequency not reported</b>: Decreased neutrophil count, decreased hemoglobin<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, rash (includes rash, generalized rash, macular rash, maculopapular rash, pruritic rash, drug eruption)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal impairment</p>
<p><b>Frequency not reported</b>: Increased serum creatinine (due to inhibition of tubular secretion of creatinine), changes in median serum creatinine<sup>[Ref]</sup></p><p>Increased serum creatinine occurred due to inhibition of tubular secretion of creatinine without affecting renal glomerular function.  Increased serum creatinine was reported within the first week of therapy and remained stable through 48 weeks; a mean change of 9.96 mcmol/L (range of -53 to 54.8 mcmol/L) was reported after 48 weeks of therapy in therapy-naive patients.  Increased serum creatinine was reported within the first 4 weeks of therapy and remained stable through 96 weeks; a mean change of 0.15 mg/dL (range of -0.32 to 0.65 mg/dL) was reported after 96 weeks of therapy in therapy-naive patients.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p>
<p><b>Frequency not reported</b>: Decreased blood bicarbonate, increased blood potassium</p>
<p><b>Postmarketing reports</b>: Increased weight</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased weight, increased blood lipid levels<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions (characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)</p>
<p><b>Frequency not reported</b>: Immune reconstitution inflammatory syndrome<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Tivicay (dolutegravir)." ViiV Healthcare, Research Triangle Park, NC. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What drugs are contained in HIV treatment Juluca?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about dolutegravir</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>24 Reviews</li>
<li>Drug class: integrase strand transfer inhibitor</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dolutegravir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Tivicay, Tivicay PD</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dolutegravir: oral tablet, oral tablet dispersible</i></p><h3>General</h3><p>The most common side effects were diarrhea, nausea, and headache.  The most common side effects of moderate to severe intensity were insomnia, fatigue, and headache.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 18%), nausea (up to 13%), elevated lipase</p><p><b>Common</b> (1% to 10%): Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting<sup>[Ref]</sup></p><p>Grade 2 and grade 3 to 4 elevations in lipase were reported in up to 11% and up to 5% of therapy-naive patients, respectively.  Elevated lipase was reported in 10% of therapy-experienced integrase strand transfer inhibitor (INSTI)-experienced patients.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 13%)</p><p><b>Common</b> (1% to 10%): Dizziness<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Grade 2 and grade 3 to 4 elevations in AST were reported in up to 5% and up to 3% of therapy-naive patients, respectively.  Grade 2 and grade 3 to 4 elevations in ALT were reported in 4% and up to 2% of therapy-naive patients, respectively.  Grade 2 and grade 3 to 4 elevations in total bilirubin were reported in up to 3% and less than 1% of therapy-naive patients, respectively.  Elevated ALT and AST were reported in 9% and 8% of therapy-experienced INSTI-experienced patients, respectively.</p><p></p><p>The rates of AST and ALT abnormalities were higher patients coinfected with hepatitis B and/or C virus.  ALT abnormalities (grade 2 to 4) in hepatitis B and/or C coinfected patients compared with HIV monoinfected patients were reported in 18% versus 3% with 50 mg once a day and 13% versus 8% with 50 mg twice a day.</p><p></p><p>Liver chemistry elevations consistent with immune reconstitution syndrome were reported in some patients with hepatitis B and/or C at the start of therapy, especially when antihepatitis therapy was stopped.</p><p></p><p>Acute liver failure has been reported in a regimen containing this drug; contribution of this drug was unclear.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated AST, elevated ALT, elevated total bilirubin, hepatitis</p><p><b>Frequency not reported</b>: Liver chemistry elevations consistent with immune reconstitution syndrome</p><p><b>Postmarketing reports</b>: Acute liver failure, hepatotoxicity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperglycemia</p><p><b>Frequency not reported</b>: Fasted lipid values increased (including cholesterol, HDL cholesterol, LDL cholesterol, triglycerides)</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased glucose levels<sup>[Ref]</sup></p><p>Grade 2 and grade 3 hyperglycemia were reported in up to 9% and up to 2% of therapy-naive patients, respectively.  Hyperglycemia and elevated cholesterol were reported in 14% and 10% of therapy-experienced INSTI-experienced patients, respectively.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Suicidal ideation, attempt, behavior, or completion were observed primarily in patients with history of depression or other psychiatric illness.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Insomnia, abnormal dreams, depression</p><p><b>Uncommon</b> (0.1% to 1%): Suicidal ideation, suicide attempt</p><p><b>Frequency not reported</b>: Suicidal behavior, suicide completion</p><p><b>Postmarketing reports</b>: Anxiety<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Grade 2 and grade 3 to 4 elevations in creatine kinase were reported in up to 5% and up to 7% of therapy-naive patients, respectively.  Elevated creatine kinase was reported in 6% of therapy-experienced INSTI-experienced patients.</p><p></p><p>Arthralgia and myalgia have also been reported during postmarketing experience.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated creatine kinase, myositis</p><p><b>Uncommon</b> (0.1% to 1%): Arthralgia, myalgia<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Grade 2 and grade 3 to 4 reductions in total neutrophils were reported in up to 4% and up to 3% of therapy-naive patients, respectively.  Hematology laboratory abnormality (grade 3 to 4) was reported in 2% of therapy-experienced INSTI-experienced patients, with neutropenia (2%) reported most often.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased total neutrophils, hematology laboratory abnormality</p><p><b>Frequency not reported</b>: Decreased neutrophil count, decreased hemoglobin<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Pruritus, rash (includes rash, generalized rash, macular rash, maculopapular rash, pruritic rash, drug eruption)<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal impairment</p><p><b>Frequency not reported</b>: Increased serum creatinine (due to inhibition of tubular secretion of creatinine), changes in median serum creatinine<sup>[Ref]</sup></p><p>Increased serum creatinine occurred due to inhibition of tubular secretion of creatinine without affecting renal glomerular function.  Increased serum creatinine was reported within the first week of therapy and remained stable through 48 weeks; a mean change of 9.96 mcmol/L (range of -53 to 54.8 mcmol/L) was reported after 48 weeks of therapy in therapy-naive patients.  Increased serum creatinine was reported within the first 4 weeks of therapy and remained stable through 96 weeks; a mean change of 0.15 mg/dL (range of -0.32 to 0.65 mg/dL) was reported after 96 weeks of therapy in therapy-naive patients.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p><p><b>Frequency not reported</b>: Decreased blood bicarbonate, increased blood potassium</p><p><b>Postmarketing reports</b>: Increased weight</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased weight, increased blood lipid levels<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions (characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)</p><p><b>Frequency not reported</b>: Immune reconstitution inflammatory syndrome<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Tivicay (dolutegravir)." ViiV Healthcare, Research Triangle Park, NC. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What drugs are contained in HIV treatment Juluca?</li>
</ul><h2>More about dolutegravir</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>24 Reviews</li>
<li>Drug class: integrase strand transfer inhibitor</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dolutegravir &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>